Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

8306	Companies
115324	Keywords
55596	Articles
62612	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 06/03/2024 at 14:00, 5 months 19 days ago

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage II
BRIEF

published on 05/31/2024 at 17:03, 5 months 21 days ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA

FDA Approval Moderna Vaccine RSV MRESVIA
PRESS RELEASE

published on 05/31/2024 at 16:58, 5 months 21 days ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
Moderna gains FDA approval for mRESVIA, a single-dose pre-filled syringe RSV vaccine for adults 60+ to prevent lower respiratory tract disease. Second mRNA product and breakthrough therapy designation

FDA Approval Moderna RSV Vaccine MRNA MRESVIA
BRIEF

published on 05/22/2024 at 13:05, 6 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Clinical Trials Immunotherapy Moderna ASCO 2024 MRNA-4157
PRESS RELEASE

published on 05/22/2024 at 13:00, 6 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Moderna to host an investor event via webcast on June 3 at 6:15 PM CDT. Abstracts on mRNA-4157 for ASCO Annual Meeting. Details on mRNA-4157 (V940) therapy development

Webcast Moderna Investor Event MRNA-4157 Neoantigen Therapy
BRIEF

published on 05/13/2024 at 13:05, 6 months 9 days ago

Moderna Announces Participation in Key Investor Conferences

Investor Conferences Healthcare Financial Markets Moderna Webcasts
PRESS RELEASE

published on 05/13/2024 at 13:00, 6 months 9 days ago

Moderna to Present at Upcoming Conferences in May/June 2024
Moderna, Inc. to participate in upcoming investor conferences, showcasing its leadership in mRNA medicine and innovative approach to disease treatment. Live webcasts available

Investor Conferences Moderna Inc. MRNA Medicine Webcasts Disease Treatment
BRIEF

published on 05/02/2024 at 12:35, 6 months 20 days ago

Moderna Reports Q1 2024 Financial Performance and Strategic Progress

Financial Results MRNA Technology Moderna RSV Vaccine Vaccine Development
PRESS RELEASE

published on 05/02/2024 at 12:30, 6 months 20 days ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024

Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula
BRIEF

published on 04/25/2024 at 13:05, 6 months 27 days ago

Moderna to Present Diverse Research Studies at ESCMID Global Congress

COVID-19 Vaccine Moderna Vaccine Research Influenza Vaccine ESCMID Congress

Accesswire

Published on 11/22/2024 at 16:00, 51 minutes ago

Manimal Tales Unveils Two New Personalized Christmas-Themed Books to Spread Holiday Magic and Joy!
Published on 11/22/2024 at 15:55, 56 minutes ago

Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Published on 11/22/2024 at 15:15, 1 hour 36 minutes ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Published on 11/22/2024 at 14:45, 2 hours 6 minutes ago

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Published on 11/22/2024 at 14:30, 2 hours 21 minutes ago

Allied Universal Named Presenting Sponsor of 2024 Lott IMPACT Trophy Recognizing College Football's Defensive Best

View all ACCESSWIRE

EQS Group

Published on 11/22/2024 at 16:00, 50 minutes ago

Proposed cancellation of admission to trading
Published on 11/22/2024 at 16:00, 50 minutes ago

AlphaX Makes Crypto Easier with Email Login and USDT Memecoins
Published on 11/22/2024 at 15:27, 1 hour 23 minutes ago

EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again
Published on 11/22/2024 at 14:46, 2 hours 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/22/2024 at 14:45, 2 hours 5 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc

Les Echos

Published on 11/22/2024 at 14:35, 2 hours 15 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 1 day 9 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 21 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 23 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 23 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE